Epidermal growth factor receptor inhibitors in non-small-cell lung cancer

Expert Opinion on Drug Discovery

Volumn 2, Issue 3, 2007, Pages 335-348

  Cascone, Tina ^a   Martinelli, Erika ^a   Morelli, Maria Pia ^a   Morgillo, Floriana ^a   Troiani, Teresa ^a   Ciardiello, Fortunato ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cetuximab; EGFR inhibitors; Epidermal growth factor receptor; Erlotinib; Gefitinib; Monoclonal antibodies; Non small cell lung cancer; Tyrosine kinase inhibitors; Vandetanib

Indexed keywords

4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EMD 27000; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; HKI 272; HR 3; IMC 225; LAPATINIB; MATUZUMAB; MEMBRANE RECEPTOR; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PANITUMUMAB; PELITINIB; PLACEBO; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG; VANDETANIB;

ANGIOGENESIS; ANOREXIA; APOPTOSIS; ASTHENIA; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER THERAPY; CARCINOGENESIS; CELL PROLIFERATION; CHILL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVITY; DRUG ERUPTION; DRUG POTENTIATION; DRUG TARGETING; DYSPNEA; EDEMA; FEVER; FLUSHING; FOLLICULITIS; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; METASTASIS; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; VOMITING;

EID: 34447521416     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.3.335     Document Type: Review

References (116)

1. MENDELSOHN J, BASELGA J: The EGF receptor family as targets for cancer therapy. Oncogene (2000) 19:6550-6565.
2. SALOMON DS, BRANDT R, CIARDIELLO F, NORMANNO N: Epidermal growth factor-related peptides and their receptors in human malignancies: an extensive review on the expression and the functional role of growth factors and receptors of the EGFR family in human cancer. Crit. Rev. Oncol. Haematol. (1995) 19:183-232.
3. SALOMON DS, GULLICK W: The ErbB family of receptors and their ligands: multiple targets for therapy. Signal (2001) 2:4-11.
4. OLAYIOYE MA, NEVE RM, LANE HA, HYNES NE: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. (2000) 19:3159-3167.
5. WOODBURN JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. (1999) 82:241-250.
6. YARDEN Y, SLIWKOWSKI MX: Untantling the ErbB signaling network. Nat. Rev. Mol. Cell. Biol. (2001) 2:127-137
7. CIARDIELLO F, TORTORA G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. (2001) 7:2958-2970.
8. GRUNWALD V, HIDALGO M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl. Cancer Inst. (2003) 95:851-867.
9. MENDELSOHN J, BASELGA J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer, J. Clin. Oncol. (2003) 21:2787-2799.
10. MENDELSOHN J: Blockade of receptors for growth factors: an anticancer therapy. Clin. Cancer Res. (2000) 6:747-753.
11. BASELGA J: Targeting EGFR with mAbs versus TKIs: different mechanisms, similar endpoints. Signal (2003) 4:4-6.
12. NORMANNO N, MAIELLO MR, DE LUCA A: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action. J. Cell. Physiol. (2003) 194:13-19.
13. CIARDIELLO F, CAPUTO R, BLANCO R et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053-2063.
14. SIROTNAK FM, ZAKOWSKY MF, MILLER VA, SCHER HI, KRIS MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD 1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. (2000) 6:4885-4892.
15. WAKELING A, GUY SP, WOODBURN JR et al.: ZD 1839 (Iressa): an orally active inhibitor of epidermal growth factor receptor signaling with potential for cancer therapy. Cancer Res. (2002) 62:5749-5754.
16. HUANG S-M, HARARI P: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. (2000) 6:2166-2174.
17. BIANCO C, TORTORA G, BIANCO R et al.: Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 ('Iressa'). Clin. Cancer Res. (2002) 8:3250-3258.
18. HUANG S, LI J, HARARI PM: Modulation of radiation response and tumor-induced angiogenesis following EGFR blockade by ZD1839 (Iressa) in human squamous cell carcinomas. Cancer Res. (2002) 62:4300-4306.
19. CIARDIELLO F, CAPUTO R, BIANCO R et al.: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. (2001) 7:1459-1465.
20. ANIDO J, MATAR P, ALBANELL J et al.: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. (2003) 9:1274-1283.
21. NORMANNO N, MAIELLO MR, DE LUCA A: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action. J. Cell Phys. (2003) 194:13-19.
22. RANSON M, HAMMOND LA, FERRY D et al.: ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial, J. Clin. Oncol. (2002) 20:2240-2250.
23. HERBST RS, MADDOX A-M, ROTHENBERG ML et al.: Selective oral epidermal growth factor receptor tyrosine inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a Phase I trial. J. Clin. Oncol. (2002) 20:3815-3828.
24. BASELGA J, RISCHIN D, RANSON M et al.: Phase I safety; pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected tumor types. J. Clin. Oncol. (2002) 21:4292-4302.
25. NAKAGAWA K, TAMURA T, NEGORO S et al.: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. (2003) 14:922-930.
26. LORUSSO P, HERBST RS, RISCHIN D et al.: Improvements in quality of life and disease-related symptoms in Phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 in non-small-cell lung cancer and other solid tumors. Clin. Cancer Res. (2003) 9:2040-2048.
27. FUKUOKA M, YANO S, GIACCONE G et al.: Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. (2003) 22:2237-2246.
28. KRIS MG, NATALE RB, HERBST RS et al.: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine, in symptomatic patients with non-small-cell lung cancer. JAMA (2003) 290:2149-2158.
29. COHEN MH, WILLIAMS GA, SRIDHARA R, CHEN G, PAZDUR R: FDA approval summary: gefitinib ZD 1839 tablets. Oncologist (2003) 8:303-306.
30. VILLANO JL, MAUER AM, VOKES EE: A case study documenting the anticancer activity of ZD 1839 in the brain. Ann. Oncol. (2003) 14:656-658.
31. CAPPUZZO F, ARDIZZONI A, SOTO-PARRA H et al.: Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small-cell lung cancer (NSCLC). Lung Cancer (2003) 41:227-231.
32. GIACCONE G, JOHNSON DH, MANEGOLD C et al.: A Phase III clinical trial of ZD 1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (INTACT 1). Ann. Oncol. (2002) 13:2 (Abstract 4).
33. JOHNSON DH, HERBST R, GIACCONE G et al.: ZD1839 in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (NSCLC): results from a Phase III clinical trial (INTACT 2). Ann. Oncol. (2002) 13:127 (Abstract 468).
34. THATCHER N, CHANG A, PARIKH P et al.: Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer. Results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet (2005) 366:1527-1537.
35. WU YL, YANG X-N, GU L-J: The characteristics of patients with non-small-cell lung cancer with complete response treated with ZD1839. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2770.
36. WONG N-S, LIM ST, LIM W-T, LEONG S-S, TAN E-H: ZD1839 is more effective in patients with non-small-cell lung cancer (NSCLC) who were lifetime non-tobacco users. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2790.
37. SHAH NT, MILLER VA, KRIS MG et al.: Bronchioalveolar histology and smoking history predict response to gefitinib. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstract 2524.
38. CIARDIELLO F, CAPUTO R, DAMIANO V et al.: Antitumor effects of ZD6474, a small molecole vascular endhotelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. (2003) 9:1546-1556.
39. CIARDIELLO F, BIANCO R, DAMIANO V et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. (2000) 6:3739-3747.
40. VAN CRUIJSEN, VOEST EE, VAN HARPEN CM et al.: Phase I clinical evaluation of AZD2171 in combination with gefitinib in patients with advanced tumors. Proc. Am. Soc. Clin. Oncol. (2005) 23:199s.
41. WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64:7099-7109.
42. ADJEI AA, MANDREKAR S, MARKS RS et al.: A Phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2005) 23:206s.
43. MOYER JD, BARBACCI EG, IWATA KK et al.: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. (1997) 57:4838-4848.
44. POLLACK VA, SAVAGE DM, BAKER DA et al.: Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. (1999) 291:739-748.
45. HIDALGO M, SIU LL, NEMUNAITIS J et al.: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. (2001) 19:3267-3279.
46. BULGARU AM, MANI S, GOEL S, PEREZ-SOLER R: Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev. Anticancer Ther. (2003) 3:269-279.
47. SOULIERES D, SENZER NN, VOKES EE et al.: Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. (2001) 22:77-85.
48. FINKLER N, GORDON A, CROZIER M et al.: Phase II evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc Am. Soc. Clin. Oncol. (2001) 20:Abstact 831.
49. PEREZ-SOLER R, CHACHOUA A, HAMMOND LA et al.: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:3238-3247.
50. SHEPHERD FA, PEREIRA J, CIULEANU TE et al.: A randomized placebo-controlled trial of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC) following failure of first line or second line chemotherapy. A National Cancer Institute of Canada Clinical Trial Group (NCIC CTG) trial. Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 7022.
51. GATZEMEIER U, PLUZANSKA A, SZCZESNA A et al.: Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine chemotehrapy in advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 7010.
52. HERBST RS, PRAGER D, HERMANN R et al.: TRIBUTE - a Phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2004) 23:Abstract 7011.
53. HERBST RS, JOHNSON DH, MININBERG E et al.: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combntion with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:2544-2555.
54. RUSNAK DW, LACKEY K, AFFLECK et al.: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. (2001) 1:85-94.
55. ROSS H, BLUMENCLEIN G-R, DOWLATI A et al.: Preliminary safty results of a Phase II trial comparing two schedules of lapatinib ( GW572016) as first line therapy for advanced or metastatic non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2005).
56. NEMUNITIS J, EISEMAN I, CUNNINGHAM C et al.: Phase I clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin. Cancer Res. (2005) 11:3846-3853.
57. CAMPOS SM, SEIDEN MV, OZA A et al.: A Phase II, single agent study of CI-1033 administered at two doses in ovarian cancer patients who failed platinum therapy. Proc. Am. Soc. Clin. Oncol. (2004)22:5054.
58. KOBAYASHI S, BOGGON TJ, DAYARAM et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2005) 352:786-792.
59. KWAK EL, SORDELLA R, BELL DW et al.: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA (2005) 102:7665-7670.
60. RABINDRAN SK, DISCAFANI CM, ROSFJORD EC et al.: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. (2004) 64:3958-3965.
61. WEDGE SR, OGILVIE DJ, DUKES M et al.: ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. (2002) 62:4646-4655.
62. CARLOMAGNO F, VITAGLIANO D, GUIDA T et al.: ZD6474, an orallyavailable inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. (2002) 62:7284-7290.
63. CIARDIELLO F, BIANCO R, CAPUTO R et al.: Antitumor activity of ZD6474, a VEGFR tyrosine kinase inhibitor, in human cancer cells with acquired resistance to anti-EGFR therapy. Clin. Cancer Res. (2004) 10:784-793.
64. WILLIAMS KJ, TELFER BA, STRATFORD IJ et al.: Schedule-dependent effects of ZD6474, a potent inhbitor of VEGFR signaling, combined with radiotherapy in a lung tumor xenograft model. Clin. Cancer Res. (2003) 9:6141S.
65. HURWITZ H, HOLDEN SN, ECKHARDT SG et al.: Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2002) 21:82a.
66. MINAMI H, EBI H, TAHARA M et al.: A Phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:194a.
67. NATALE R, BODKIN D, GOVINDAN R et al.: A comparison of the antitumor efficacy of ZD6474 and gefitinib (Iressa) in patients with NSCLC:results of a randomised, double bind, Phase II study. Lung Cancer (2005) 49(Suppl. 2):s37.
68. HEYMACH JV, WEST H, KERR et al.: ZD6474 in combination with carboplatin and paclitaxel as first-line treatment in patients with NSCLC: results of the run-in phase of a two-part randomized Phase II study. Lung Cancer (2005) 49(Suppl. 2):S247 (Abstract P-497).
69. HEYMACH JV, JOHNSON BE, PRAGER D et al.: A Phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. J. Clin. Oncol. (2006) 24:368s (Abstract 7016).
70. GOLDSTEIN NI, PREWETT M, ZUKLYS K, ROCKWELL P, MENDELSOHN J: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. (1995) 1:1311-1318.
71. WU X, RUBIN M, FAN Z et al.: Involvement of p27kip 1 in G 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene (1996) 12:1397-1403.
72. PENG D, FAN Z, LU Y, DEBLASIO T, SCHER H, MENDELSOHN J: Anti-epidermal growth factor receptor monoclonal antibody C225 upregulates p27kip1 and induces G 1 arrest in prostatic cancer cell line DU145. Cancer Res. (1996) 56:3666-3669.
73. CIARDIELLO F, DAMIANO V, BIANCO R et al.: Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. NatL Cancer Inst. (1996) 88:1770-1776.
74. CIARDIELLO F, BIANCO R, DAMIANO V et al.: Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin. Cancer Res. (1999) 5:909-916.
75. PREWETT M, ROTHMAN M, WAKSAL H, FELDMAN M, BANDER NH, HICKLIN DJ: Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin. Cancer Res. (1998) 4:2957-2966.
76. PERROTTE P, MATSUMOTO T, INOUE K et al.: Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. (1999) 5:257-265.
77. BRUNS CJ HARBISON MT, DAVIS DW et al.: Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin. Cancer Res. (2000) 6:1936-1948.
78. CIARDIELLO F, BIANCO R, DAMIANO V et al.: Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin. Cancer Res. (2000) 6:3739-3747.
79. INOUE K, SLATON JW, PERROTTE P et al.: Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin. Cancer Res. (2000) 6:4874-4884.
80. SALEH MH, RAISCH KP, STACKHOUSE MA et al.: Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother. Radiopharm. (1999) 14:451-463.
81. MILAS L, MASON K, HUNTER N et al.: In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res. (2000) 6:701-708.
82. HUANG SM, BOCK JM, HARARI PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. (1999) 15:1935-1940.
83. BIANCO C, BIANCO R, TORTORA G et al.: Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin. Cancer Res. (2000) 6:4343-4350.
84. HUANG S-M, HARARI P: Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. (2000) 6:2166-2174.
85. BASELGA J, PFISTER D, COOPER MR et al.: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. (2000) 18:904-914.
86. ROBERT F, BLUMENSCHEIN G, DICKE K et al.: Phase IB/IIA study of anti-epidermal growth factor receptor antibody, cetuximab, in combination with gemcitabine/carboplatin in patients with advanced stage IV non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 23:Abstract 2587.
87. KELLY K, HANNA N, ROSENBERG A et al.: A multicenter Phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2003) 23:Abstract 2592.
88. KIM ES, MAUER AM, TRAN HT et al.: A Phase II study of Cetuximab, an IgG1 epidermal growth factor receptor-blocking antibody, in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer: final report. Proc. Am. Soc. Clin. Oncol. (2003) 23:Abstract 2581.
89. GATZEMEIER U, ROSELL R, RAMLAU R et al.: Cetuximab (C225) in combination with cisplatin/vinorelbin versus cisplatin/vinorelbin alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2003) 23:Abstract 2582.
90. KELLY K, HERBST RS, CROWLEY JJ et al.: Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small-cell lung cancer (NSCLC): a randomized Phase II selectional trial SWOG 0342. Proc. Am. Soc. Clin. Oncol. (2006) 24:Abstract 7015.
91. WEINER LM, BELLDEGRUN A, ROWINSKY E et al.: Updated results from a dose and schedule study of panitumumab (ABX-EGF) monotherapy, in patients with advanced solid maligmancies. Proc. Am. Soc. Clin. Oncol. (2005) 23:3059.
92. DOI T, OHTSU A, SAIJO N et al.: A Phase I study of humanized monclonalanti-epidermal growth factor receptor (EGFR) antibody 'EM72000 (Matuzumab)' administered weekly in Japanese patients with advanced solid tumors; safety, PK, and PD results of kin biopsies. Proc. Am. Soc. Clin. Oncol. (2005) 23:3077.
93. RAO S, STARLING N, BENSON A et al.: Phase I stdy of the humanized epidermal growth factor receptor (EGFR) antibody EMD72000 (matuzumab) in combination with ECX (epirubicin, cisplatin and capecitabine) as first line treatment for advanced oesophagogastric (OG) adenocarcinoma. Proc. Am. Soc. Clin. Oncol. (2005) 24.
94. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350:2129-2139.
95. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304:1497-1500.
96. PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101:13306-13311.
97. GREULICH H, CHEN TH, FENG W et al.: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PloS Med. (2005) 2:e313.
98. EBERHARD DA, JOHNSON BE, AMLER LC et al.: Mutatuons in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J. Clin. Oncol. (2005) 23:5900-5909.
99. SHIGEMATSU H, GAZDAR AF: Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancer. Int. J. Cancer (2006) 118:257-262.
100. BELL DW, LYNCH TJ, HASERLAT SM et al.: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. (2005) 23:8081-8092.
101. MITSUDOMI T, KOSAKA T, ENDOH H et al.: Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence, J. Clin. Oncol. (2005) 23:2513-2520.
102. TAKANO T, OHE Y, YOSHIDA H et al.: Evaluation of epidermal growth factor receptor mutations and gene copy numbers as predictors of clinical outcomes in Japanese patients with recurrent non-small-cell lung cancer (NSCLC) receiving gefitinib. ASCO (2005):7032.
103. SHIH JY, GOW CH, YU CJ et al.: Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced non small cell lung cancer. Int. J. Cancer (2006) 118:963-969.
104. CHOU TY, CHIU CH, LI LH et al.: Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and progostic factor for gefitinib treatment in patients with non-small-cell lung cancer. Clin. Cancer Res. (2005) 11:3750-3757.
105. HAN SW, KIM TY, HWANG PG et al.: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. (2005) 23:2493-2501.
106. TARON M, ICHINOSE Y, ROSELL E et al.: Activating mutations in the tyrosine kinasedomain of epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. (2005) 11:5878-5885.
107. CAPPUZZO F, HIRSCH FR, ROSSI E et al.: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. (2005) 97:643-655.
108. TOKUMO M, TOYOOKA S, KIURA K et al.: The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small-cell lung cancers. Clin. Cancer Res. (2005) 11:1167-1173.
109. CORTES-FUNES H, GOMEZ C, ROSELL R et al.: Epidermal growth factor receptor activiting mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann. Oncol. (2005) 16:1081-1086.
110. TSAO MS, SAKURADA A, CUTZ JC et al.: Erlotinib in lung cancer-molecular and clinical predictors of outcomes. N. Engl. J. Med. (2005) 353:133-144.
111. INOUE A, SUZUKI T, FUKUHARA T et al.: Prospective Phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. (2006) 24:3340-3346.
112. MORIKAWA A, INOUE A, SUZUKI T et al.: Prospective analysis of the epidermal growth factor receptor gene mutations in non-small-cell lung cancer in Japan. J. Clin. Oncol. (2006) 24:18s (Abstract 7077).
113. SUNAGA N, YANAGITANI N, KAIRA K et al.: Phase II study of the efficacy of gefitinib in patients with non-small-cell lung cancer with the EGFR mutations. J. Clin. Oncol. (2006)24:18s (Abstract 77183).
114. SUTANI A, NAGAI Y, UDAGAWA K et al.: Phase II study of gefiitinib for non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) gene mutations detected by PNA-LNA PCR clamp. J. Clin. Oncol. (2006) 24:18s (Abstract 77183).
115. PAZ-ARES L, SANCHEZ JM, GARCIA-VALESCO A et al.: A prospective Phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). J. Clin. Oncol. (2006) 24:7020.
116. KAYE FJ: A curious link between epidermal growth factor receptor amplification and survival: effect of 'allele dilution' on gefitinib sensitivity? J. Natl. Cancer Inst. (2005) 97:621-623.